Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Atrial fibrillation (AF) is a chronic disease often coexisting with coronary artery disease (CAD).
• Approximately 5-15% of AF patients require percutaneous coronary intervention (PCI).
• Managing concomitant AF and CAD necessitates balancing bleeding risk against ischemic events like stroke and myocardial infarction.

Purpose of the Study:

• To review current evidence and rationale for antithrombotic treatment strategies in patients with both AF and CAD.
• To guide therapeutic choices for oral anticoagulation (OAC) and antiplatelet therapy.
• To tailor treatment based on individual patient's coronary presentation.

Main Methods:

• Review of existing literature on antithrombotic therapies in AF and CAD.
• Analysis of the comparative efficacy and risks of OAC and antiplatelet agents.
• Focus on personalized treatment strategies based on coronary syndromes.

Main Results:

• Dual antiplatelet therapy (DAPT) is superior for preventing coronary events but increases stroke risk compared to OAC alone in AF patients.
• OAC is crucial for preventing stroke and systemic embolism in AF patients.
• Balancing antithrombotic therapy is critical to mitigate risks.

Conclusions:

• Antithrombotic treatment in patients with AF and CAD requires careful consideration of individual risk profiles.
• Tailoring OAC and antiplatelet therapy based on the specific coronary presentation is essential.
• Optimizing treatment strategies can improve outcomes by managing both bleeding and ischemic risks.